Aim for the brain: RA Cap­i­tal bets on Col­orado biotech to re­for­mu­late epilep­sy drug for re­frac­to­ry pa­tients

A decades-old an­ti-epilep­tic drug, linked to de­for­mi­ties in un­born chil­dren, is be­ing re­for­mu­lat­ed for in­jec­tion straight in­to the brain of pa­tients whose epilep­sy has per­sist­ed de­spite ther­a­py.

On Tues­day, the com­pa­ny be­hind the ef­fort — Au­ro­ra, Col­orado-based Cere­bral Ther­a­peu­tics — scored $35 mil­lion in Se­ries B fi­nanc­ing led by RA Cap­i­tal Man­age­ment to fund a Phase IIb tri­al of its drug-de­vice com­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER